SEC Tracker
Get the app

Halozyme Therapeutics HALO

Halozyme Therapeutics reported $247.05 million net income for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $492.97 million for the three months ended Sep 30, 2026.
  2. Net income of $247.05 million for the three months ended Sep 30, 2026.
  3. Diluted EPS of $2.01 for the three months ended Sep 30, 2026.
  4. Cash and equivalents of $1.03 billion as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Halozyme Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  2. Alkermes ALKS public float $4.7B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.